A study found that DCs in tumor lysate could consistently activate CD8+ CTLs for killing cancer cells in locally advanced BC, indicating DC-based vaccinations might be well suited to treat chemotherapy-resistant BC patients (83). The gene discussed is CD8A; the disease is neoplasm.